Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
The Sydney Diabetes Clinical Research Unit (SDCRU) is a premier clinical trial site and research organization based in Sydney, Australia, specializing in metabolic and endocrine disorders. Affiliated with major healthcare institutions like the Royal Prince Alfred Hospital, the unit conducts Phase 1 through Phase 4 clinical trials for global pharmaceutical and biotechnology partners. Their expertise encompasses the evaluation of novel pharmacotherapies, including GLP-1 receptor agonists and SGLT2 inhibitors, as well as advanced medical devices such as continuous glucose monitors and automated insulin delivery systems. SDCRU is recognized for its multidisciplinary approach, integrating clinical care with cutting-edge research to improve outcomes for patients with diabetes and related complications.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Sydney Diabetes Clinical Research Unit.